Exercise Capacity After Repair of Ebstein Anomaly in Adults.


Journal

Pediatric cardiology
ISSN: 1432-1971
Titre abrégé: Pediatr Cardiol
Pays: United States
ID NLM: 8003849

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 25 06 2018
accepted: 16 01 2019
pubmed: 1 2 2019
medline: 14 5 2019
entrez: 1 2 2019
Statut: ppublish

Résumé

Repair of Ebstein anomaly has evolved over the last decade, and timing of repair remains variable. There have been no studies of exercise or functional capacity in patients who have had tricuspid valve surgery for Ebstein anomaly in adulthood. We aimed to compare exercise capacity before and after tricuspid valve repair or replacement for Ebstein anomaly in adults at Mayo Clinic. We performed a retrospective chart review of all patients with Ebstein anomaly who underwent tricuspid valve surgery at Mayo Clinic between June 2007 and January 2015. We compared pre- and postoperative echocardiograms, exercise tests, and clinic visits. Tricuspid valve surgery was done for 322 patients, and 32 patients met criteria of native tricuspid valve repair or replacement at age 18 or older and had maximal pre- and postoperative exercise tests. Nineteen patients had valve repair, and 13 had valve replacement. Surgery for Ebstein anomaly resulted in significant reduction in tricuspid regurgitation and right ventricular size. There was a significant improvement in NYHA functional class after surgery; however, there was no significant improvement in functional aerobic capacity (FAC), metabolic equivalents (METs), exercise time, or [Formula: see text] after surgery. Patients who had an atrial shunt closed during surgery had improved minimum blood oxygen saturations during exercise, though no improvement in exercise capacity. In our cohort, patients who had tricuspid valve repair or replacement for Ebstein anomaly reported an improvement in functional capacity; however, this did not reflect improvement in measured exercise capacity, despite excellent surgical results by echocardiography.

Identifiants

pubmed: 30701277
doi: 10.1007/s00246-019-02056-9
pii: 10.1007/s00246-019-02056-9
doi:

Substances chimiques

Adrenergic beta-Antagonists 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

726-732

Références

J Thorac Cardiovasc Surg. 2007 Jan;133(1):215-23
pubmed: 17198815
J Am Coll Cardiol. 2008 Aug 5;52(6):460-6
pubmed: 18672167
J Thorac Cardiovasc Surg. 2011 May;141(5):1192-5
pubmed: 21093874
Clin Cardiol. 1990 Aug;13(8):555-65
pubmed: 2204507
Am Heart J. 2012 Mar;163(3):486-91
pubmed: 22424021
Congenit Heart Dis. 2014 May-Jun;9(3):266-71
pubmed: 24373319
J Thorac Cardiovasc Surg. 2015 Apr;149(4):1144-50
pubmed: 25702323
Int J Cardiol. 2016 Feb 15;205:1-5
pubmed: 26703376
Int J Cardiol. 2016 Sep 1;218:79-82
pubmed: 27232916
J Am Coll Cardiol. 1988 Apr;11(4):831-6
pubmed: 3351151
J Am Coll Cardiol. 1997 Jun;29(7):1615-22
pubmed: 9180127

Auteurs

Brandon D Morrical (BD)

Department of Pediatric Cardiology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.

Joseph A Dearani (JA)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA.

Crystal R Bonnichsen (CR)

Divsion of Cardiology, Department of Adult Congenital Cardiology, Mayo Clinic, Rochester, MN, USA.

Nathaniel W Taggart (NW)

Department of Pediatric Cardiology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. Taggart.Nathaniel@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH